subject: Aarkstore Enterprise---global Breast Cancer Drugs Market 2009-2013 [print this page] Every year, more than a million women are diagnosed with breast cancer, worldwide. Breast cancer is the most common type of cancer and second leading cause of death in women, preceded only by lung cancer. Though women of all ages have risk of developing breast cancer, older woman have greater chances of developing it. The incidence rate of breast cancer varies considerably; registering the highest rate in the North America and the lowest rate in Africa and Asia.
The market for Breast Cancer Drugs represents an area of potential opportunity in both developed and developing countries. As a result, a large number of companies (pharmaceutical and biotechnology) are focusing to develop innovative breast cancer drugs. Further, the companies are forming alliances and agreements to develop effective treatments for breast cancer. Strategic acquisitions are also on rise to explore new markets and strengthen R&D.
The introduction of newer cancer drugs shows promise in effective treatment of breast cancer. The enhanced focus on tailored drug delivery in breast cancer treatment is likely to support growth in Breast Cancer Drugs market. However, the time and high cost involved in developing and approving a cancer drug remains a major challenge in the market.
This report highlights the scope of the Global Breast Cancer Drugs market 2009-2013, along with trends, drivers, growth inhibitors and a few major vendors in the market.
